Johnson Barbara W, Chambers Trudy V, Crabtree Mary B, Guirakhoo Farshad, Monath Thomas P, Miller Barry R
Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado 80521, USA.
Am J Trop Med Hyg. 2004 Jan;70(1):89-97.
The vector competence of mosquitoes for chimeric viruses being developed as vaccines to protect against dengue (DEN) virus infection were evaluated in a cooperative agreement with Acambis, Inc. Chimeric viruses have been constructed that contain the premembrane (prM) and envelope (E) genes of each of the wild-type (wt) DEN virus serotypes, DEN-1, DEN-2, DEN-3, and DEN-4, in the yellow fever (YF) vaccine virus (strain 17D) YF-VAX backbone. It was previously shown that the replication profile of ChimeriVax-DEN2 virus in Aedes albopictus C6/36 cells and in vivo in Ae. aegypti mosquitoes corresponded to that of YF-VAX virus; replication was restricted in C6/36 cells, and Ae. aegypti were poorly infected via an artificial infectious blood meal. Thus, there is very little risk of transmission by mosquitoes of ChimeriVax-DEN2 vaccine virus through the bite of a mosquito. However, because ChimeriVax-DEN 1, 2, 3, 4 viruses will be administered to humans simultaneously, growth of a mixture of ChimeriVax-DEN 1, 2, 3, 4 viruses was assessed in both C6/36 cells in culture and in the Ae. aegypti mosquito, which is the primary vector of both YF and DEN viruses. Mosquitoes were intrathoracically (IT) inoculated with virus or fed a virus-laden blood meal, and the replication kinetics of ChimeriVax-DEN 1, 2, 3, 4 were compared with the wt DEN and YF-VAX viruses. A quantitative real-time reverse transcriptase-polymerase chain reaction assay was developed as a method to detect and differentiate replication of each of the four ChimeriVax-DEN serotypes in the ChimeriVax-DEN 1, 2, 3, 4 tetravalent mixture. Growth of the chimeric viruses in C6/36 cells and in IT-inoculated Ae. aegypti was lower than that of YF-VAX virus; in previous studies Ae. aegypti was shown to be refractory to infection by YF-VAX virus. The growth rate of each chimeric virus was similar whether it was a single serotype infection, or part of the tetravalent mixture, and no interference by one chimeric virus over another chimeric serotype was observed. ChimeriVax-DEN viruses infected mosquitoes poorly via an infectious blood meal compared with wt DEN viruses. Therefore, it is unlikely that a mosquito feeding on a viremic vaccinee, would become infected with the chimeric viruses. Thus, there is very little potential for transmission by mosquitoes of the ChimeriVax-DEN vaccine viruses.
与阿坎比斯公司签订合作协议,评估了作为预防登革热(DEN)病毒感染疫苗而研发的嵌合病毒在蚊子中的传播能力。已构建出嵌合病毒,其在黄热病(YF)疫苗病毒(17D株)YF-VAX主干中包含野生型(wt)DEN病毒血清型DEN-1、DEN-2、DEN-3和DEN-4各自的前膜(prM)和包膜(E)基因。先前已表明,嵌合登革2型病毒(ChimeriVax-DEN2)在白纹伊蚊C6/36细胞中和埃及伊蚊体内的复制情况与YF-VAX病毒的复制情况相符;在C6/36细胞中复制受到限制,并且通过人工感染性血餐对埃及伊蚊的感染效果不佳。因此,ChimeriVax-DEN2疫苗病毒通过蚊子叮咬传播的风险非常小。然而,由于将同时给人类接种ChimeriVax-DEN 1、2、3、4病毒,所以在培养的C6/36细胞和作为YF和DEN病毒主要传播媒介的埃及伊蚊中评估了ChimeriVax-DEN 1、2、3、4病毒混合物的生长情况。用病毒对蚊子进行胸腔内(IT)接种或喂食含病毒的血餐,并将ChimeriVax-DEN 1、2、3、4的复制动力学与野生型DEN病毒和YF-VAX病毒进行比较。开发了一种定量实时逆转录聚合酶链反应测定法,作为检测和区分ChimeriVax-DEN 1、2、3、4四价混合物中四种ChimeriVax-DEN血清型各自复制情况的方法。嵌合病毒在C6/36细胞和经IT接种埃及伊蚊中的生长低于YF-VAX病毒;在先前的研究中已表明埃及伊蚊对YF-VAX病毒的感染具有抗性。无论嵌合病毒是单一血清型感染还是四价混合物的一部分,其生长速率都相似,并且未观察到一种嵌合病毒对另一种嵌合血清型的干扰。与野生型DEN病毒相比,ChimeriVax-DEN病毒通过感染性血餐对蚊子的感染效果不佳。因此,吸食病毒血症疫苗接种者血液的蚊子不太可能感染嵌合病毒。因此,ChimeriVax-DEN疫苗病毒通过蚊子传播的可能性非常小。